The applications of PET in clinical oncology - PubMed (original) (raw)
Review
. 1991 Apr;32(4):623-48; discussion 649-50.
Affiliations
- PMID: 2013803
Free article
Review
The applications of PET in clinical oncology
L G Strauss et al. J Nucl Med. 1991 Apr.
Free article
Abstract
With the advent of a new generation of PET scanners that have introduced whole-body PET to the clinical setting, there is now more interest in developing protocols for the evaluation of both intracranial and somatic cancers. The value of PET in clinical oncology has been demonstrated with studies in a variety of cancers including colorectal carcinomas, lung tumors, head and neck tumors, primary and metastatic brain tumors, breast carcinoma, lymphoma, melanoma, bone cancers, and other soft-tissue cancers. A summary of current clinical applications of PET in oncology is presented with special attention to colorectal, lung, and intracranial neoplasms since the majority of clinical trials have focused on these cancers. A variety of radiopharmaceuticals are described that are currently included in clinical tumor-imaging protocols, including metabolic substrates such as fluorine-18-fluorodeoxyglucose and carbon-11-methionine, and analogs of chemotherapeutic agents such as fluorine-18-fluorouracil and fluoroestradiol. An attempt is also made to include examples of clinical trials that demonstrate response to therapeutic intervention. The increasing number of oncologic PET studies reflects the growing interest in functional imaging in oncology.
Similar articles
- Use of positron emission tomography in oncology.
Glaspy JA, Hawkins R, Hoh CK, Phelps ME. Glaspy JA, et al. Oncology (Williston Park). 1993 Jul;7(7):41-6, 49-50; discussion 50-2, 55. Oncology (Williston Park). 1993. PMID: 8347460 Review. - [Diagnostic value of positron emission tomography (PET) in clinical oncology].
Czech N, Brenner W, Kampen WU, Henze E. Czech N, et al. Dtsch Med Wochenschr. 2000 May 5;125(18):565-7. doi: 10.1055/s-2007-1024342. Dtsch Med Wochenschr. 2000. PMID: 10835983 Review. German. No abstract available. - Clinical role of positron emission tomography in oncology.
Bomanji JB, Costa DC, Ell PJ. Bomanji JB, et al. Lancet Oncol. 2001 Mar;2(3):157-64. doi: 10.1016/s1470-2045(00)00257-6. Lancet Oncol. 2001. PMID: 11902566 Review. - [Role of 18F-FDG positron emission tomography in surgical evaluation].
Franzius C, Sciuk J, Schober O. Franzius C, et al. Langenbecks Arch Chir Suppl Kongressbd. 1998;115:261-9. Langenbecks Arch Chir Suppl Kongressbd. 1998. PMID: 9931622 Review. German.
Cited by
- Evaluation of bone remodeling with (18)F-fluoride and correlation with the glucose metabolism measured by (18)F-FDG in lumbar spine with time in an experimental nude rat model with osteoporosis using dynamic PET-CT.
Cheng C, Heiss C, Dimitrakopoulou-Strauss A, Govindarajan P, Schlewitz G, Pan L, Schnettler R, Weber K, Strauss LG. Cheng C, et al. Am J Nucl Med Mol Imaging. 2013;3(2):118-28. Epub 2013 Mar 8. Am J Nucl Med Mol Imaging. 2013. PMID: 23526138 Free PMC article. - F18-FDG-PET/CT for evaluation of intraductal papillary mucinous neoplasms (IPMN): a review of the literature.
Bertagna F, Treglia G, Baiocchi GL, Giubbini R. Bertagna F, et al. Jpn J Radiol. 2013 Apr;31(4):229-36. doi: 10.1007/s11604-012-0176-2. Epub 2013 Jan 12. Jpn J Radiol. 2013. PMID: 23315020 Review. - Quantification of metabolic tumor activity and burden in patients with non-small-cell lung cancer: Is manual adjustment of semiautomatic gradient-based measurements necessary?
Obara P, Liu H, Wroblewski K, Zhang CP, Hou P, Jiang Y, Chen P, Pu Y. Obara P, et al. Nucl Med Commun. 2015 Aug;36(8):782-9. doi: 10.1097/MNM.0000000000000317. Nucl Med Commun. 2015. PMID: 25888358 Free PMC article. Clinical Trial. - 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET.
Kim S, Chung JK, Im SH, Jeong JM, Lee DS, Kim DG, Jung HW, Lee MC. Kim S, et al. Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):52-9. doi: 10.1007/s00259-004-1598-6. Epub 2004 Aug 10. Eur J Nucl Med Mol Imaging. 2005. PMID: 15309332 - The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.
Kasper B, Schmitt T, Wuchter P, Dimitrakopoulou-Strauss A, Ho AD, Egerer G. Kasper B, et al. Mar Drugs. 2009 Jul 17;7(3):331-40. doi: 10.3390/md7030331. Mar Drugs. 2009. PMID: 19841717 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources